<DOC>
	<DOC>NCT02288520</DOC>
	<brief_summary>This is a longitudinal, observational, prospective, multicentre study conducted in metropolitan France, among a representative sample of office-based or mixed practice rheumatology doctors. The aim of this study is to describe in real life, the therapy strategy when faced with a patient treated with methotrexate as a monotherapy consulting for rheumatoid arthritis and the impact on the progression of the disease at 6 months.</brief_summary>
	<brief_title>Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient, ambulatory, seen in a rheumatology consultation. With a confirmed diagnosis of RA (ACR 1987 or ACR/EULAR 2010 criteria) receiving a diseasemodifying treatment with methotrexate as a monotherapy. With clinical, functional, structural and/or therapeutic disease progression, for whom the rheumatologist intends to change the therapeutic treatment of the RA . Informed about the computer processing of their medical data and their right of access and correction. Patient not treated with methotrexate for their RA. Already treated with a biotherapy or receiving other synthetic DMARDs (diseasemodifying antirheumatic drugs) in combination with methotrexate . Participating in a clinical trial in rheumatology.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Therapeutic strategy</keyword>
</DOC>